Medically reviewed content. Written by Joe Miller, BS Kinesiology & Exercise Science, A4M Fellowship, NASM & NSCA CSCS Certified. Last updated March 2026.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications require a prescription and should only be used under the supervision of a licensed healthcare provider. Individual results vary. Consult your physician before starting any weight loss medication.
GLP-1 weight loss medications have transformed the landscape of medical weight management. With clinical trials showing 15 to 22 percent body weight reduction, these medications offer a science-backed solution for individuals who have struggled with traditional approaches. Understanding how GLP-1 medications work, what results to expect, and whether you are a good candidate can help you make an informed decision about your weight loss journey.
What Are GLP-1 Medications?
GLP-1 medications belong to a class of drugs called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone your body produces in the small intestine after eating. This hormone plays a central role in regulating blood sugar, insulin secretion, and appetite.
GLP-1 receptor agonist medications mimic the action of natural GLP-1 but are engineered to last significantly longer in the body. While your natural GLP-1 is broken down within minutes, these medications remain active for days, providing sustained metabolic benefits. Originally developed to treat type 2 diabetes, researchers discovered that GLP-1 receptor agonists produced significant weight loss as a secondary effect, leading to FDA approval for chronic weight management.
How GLP-1s Promote Weight Loss
GLP-1 medications drive weight loss through multiple complementary mechanisms that work together to reduce caloric intake and improve metabolic function.
Appetite suppression and satiety signaling: GLP-1 receptor agonists act directly on the hypothalamus, the brain region responsible for hunger regulation. By activating GLP-1 receptors in the brain, these medications enhance feelings of fullness and reduce the reward-driven desire to eat, making it easier to eat smaller portions without feeling deprived.
Delayed gastric emptying: These medications slow the rate at which food moves from the stomach into the small intestine. This means food stays in your stomach longer, extending the feeling of fullness after meals and naturally reducing the urge to eat again soon.
Blood sugar regulation: GLP-1 receptor agonists stimulate glucose-dependent insulin secretion while suppressing glucagon release. This stabilizes blood sugar levels throughout the day, reducing the energy crashes and intense cravings that often derail weight loss efforts.
Reduced caloric intake: The combined effect of enhanced satiety, slower digestion, and stable blood sugar typically leads to a 20 to 40 percent reduction in daily caloric intake without requiring extreme willpower or restrictive dieting.
GLP-1 Medications Available for Weight Loss
Several GLP-1 medications are currently available, each with distinct characteristics. Here is how the primary options compare:
| Medication | Active Ingredient | FDA-Approved For Weight Loss | Dosing Frequency | Average Weight Loss |
|---|---|---|---|---|
| Wegovy | Semaglutide 2.4 mg | Yes | Weekly injection | 15–17% |
| Ozempic | Semaglutide 0.5–2 mg | No (diabetes; used off-label) | Weekly injection | 10–15% |
| Zepbound | Tirzepatide 5–15 mg | Yes | Weekly injection | 20–26% |
| Mounjaro | Tirzepatide 5–15 mg | No (diabetes; used off-label) | Weekly injection | 18–22% |
| Saxenda | Liraglutide 3 mg | Yes | Daily injection | 5–10% |
Compounded semaglutide is also available through licensed compounding pharmacies under specific FDA guidelines, offering an alternative access pathway for eligible patients. Tirzepatide is a dual GIP/GLP-1 receptor agonist, which means it activates two incretin pathways simultaneously, potentially explaining its higher efficacy in clinical trials.
Clinical Trial Results
The evidence supporting GLP-1 weight loss is robust, with multiple large-scale randomized controlled trials published in top medical journals including the New England Journal of Medicine.
STEP Trials (Semaglutide)
The Semaglutide Treatment Effect in People with Obesity (STEP) program includes five pivotal trials:
- STEP 1 (NEJM, 2021): Participants receiving semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. One-third of participants lost over 20% of their body weight.
- STEP 2: In adults with type 2 diabetes, semaglutide produced 9.6% weight loss over 68 weeks.
- STEP 3: Combined with intensive behavioral therapy, semaglutide resulted in 16% body weight loss over 68 weeks.
- STEP 4: Participants who continued semaglutide maintained weight loss, while those switched to placebo regained weight, demonstrating the importance of ongoing treatment.
- STEP 5: Extended 104-week data showed sustained 15.2% weight loss over two years of continuous treatment.
SURMOUNT Trials (Tirzepatide)
The SURMOUNT trial program evaluated tirzepatide for weight management:
- SURMOUNT-1 (NEJM, 2022): Participants on the highest dose (15 mg) lost an average of 22.5% of body weight over 72 weeks. More than one-third of participants achieved at least 25% weight loss, with some reaching up to 26% reduction.
- SURMOUNT-2: In participants with type 2 diabetes, tirzepatide 15 mg produced 14.7% weight loss over 72 weeks.
SCALE Trial (Liraglutide)
The SCALE Obesity and Prediabetes trial (NEJM, 2015) showed liraglutide 3.0 mg produced 8% body weight loss over 56 weeks, with 33.1% of participants losing at least 10% of body weight.
These results demonstrate meaningful, clinically significant weight loss that exceeds what is typically achievable through lifestyle changes alone. Most patients begin seeing results within 4 to 8 weeks, with maximum weight loss typically occurring between 12 and 18 months of treatment.
Who Is a Good Candidate for GLP-1 Weight Loss?
GLP-1 medications are typically appropriate for adults who meet certain clinical criteria:
General eligibility includes:
- BMI of 30 or higher (obesity), or
- BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea
- History of unsuccessful weight loss attempts through diet and exercise alone
Metabolic health markers that may indicate benefit:
- Elevated fasting insulin or insulin resistance (HOMA-IR)
- Elevated hemoglobin A1c (prediabetes range 5.7–6.4%)
- Elevated triglycerides or unfavorable cholesterol ratios
- Visceral adiposity (excess belly fat)
Who should avoid GLP-1 medications:
- Individuals with a personal or family history of medullary thyroid carcinoma (MTC)
- Those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with a history of pancreatitis should use caution
- Pregnant or breastfeeding women
- Individuals with a history of severe gastrointestinal disease
A thorough medical evaluation, including comprehensive lab work, is essential before starting GLP-1 therapy to assess candidacy and identify any potential contraindications.
Common Side Effects and How to Manage Them
Most GLP-1 side effects are gastrointestinal and tend to be mild to moderate, often improving within the first few weeks of treatment.
Common side effects include:
- Nausea (most common, reported in 20–44% of patients)
- Diarrhea (reported in 15–30% of patients)
- Constipation (reported in 10–24% of patients)
- Vomiting (typically during dose escalation)
- Abdominal pain or bloating
- Decreased appetite (intended therapeutic effect)
The titration approach: The most effective strategy for minimizing side effects is gradual dose escalation, also known as titration. Treatment starts at a low dose and increases incrementally every 4 weeks, giving your body time to adjust. For example, semaglutide begins at 0.25 mg weekly and gradually increases to the target dose of 2.4 mg over 16 to 20 weeks.
Additional management strategies:
- Eat smaller, more frequent meals
- Avoid high-fat or greasy foods during dose adjustments
- Stay well-hydrated
- Eat slowly and stop at the first sign of fullness
- Work with your prescribing provider to adjust the titration timeline if side effects are significant
Serious side effects are rare but may include pancreatitis, gallbladder problems, and allergic reactions. Report any severe or persistent symptoms to your healthcare provider immediately.
GLP-1s vs Other Weight Loss Approaches
Understanding how GLP-1 medications compare to other weight loss methods helps set realistic expectations.
GLP-1 medications vs diet and exercise alone: Lifestyle interventions typically produce 3 to 5 percent body weight loss. GLP-1 medications, combined with lifestyle changes, produce 15 to 22 percent, representing a three- to five-fold improvement. Importantly, GLP-1 medications work best when paired with proper nutrition and regular physical activity.
GLP-1 medications vs bariatric surgery: Bariatric surgery (gastric bypass, gastric sleeve) produces 25 to 35 percent weight loss but carries surgical risks, requires permanent anatomical changes, and involves a longer recovery period. GLP-1 medications offer a non-surgical alternative with comparable results at the higher end of the spectrum, particularly with tirzepatide.
GLP-1 medications vs older weight loss drugs: Earlier weight loss medications (phentermine, orlistat) typically produce 5 to 10 percent weight loss and often come with more side effects or shorter approved treatment durations. GLP-1 receptor agonists offer superior efficacy with a well-characterized safety profile and approval for long-term use.
What Happens When You Stop GLP-1 Medications?
One of the most important considerations with GLP-1 therapy is what occurs after discontinuation.
Weight regain data: The STEP 4 trial demonstrated that participants who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight within 48 weeks. A 2023 follow-up analysis published in Diabetes, Obesity and Metabolism found that most weight regain occurs within the first year of stopping treatment.
Why weight regain occurs: Obesity involves persistent changes in hunger hormones, metabolic rate, and brain appetite signaling. When GLP-1 medication is discontinued, these biological drivers of weight regain reassert themselves, similar to how blood pressure returns to elevated levels when antihypertensive medication is stopped.
Maintenance strategies:
- Long-term or ongoing treatment at a maintenance dose may be appropriate for many patients
- Stepped-down dosing under medical supervision can help find the minimum effective dose
- Lifestyle optimization including regular strength training, adequate protein intake, and consistent physical activity helps preserve lean mass and metabolic rate
- Metabolic monitoring through regular lab work helps track hormone levels, metabolic markers, and body composition changes over time
- Comprehensive care coordination with a medical team ensures adjustments are made proactively rather than reactively
How 1st Optimal’s GLP-1 Medical Weight Loss Program Works
At 1st Optimal, our GLP-1 weight loss program goes beyond simply prescribing medication. We take a comprehensive, data-driven approach designed for lasting results.
Comprehensive lab testing: Every program begins with in-depth diagnostic testing, including a complete metabolic panel, fasting insulin, hemoglobin A1c, lipid panel, thyroid function, and inflammatory markers. This baseline data informs every clinical decision and helps identify underlying metabolic factors that may be contributing to weight gain.
Personalized medication selection: Based on your lab results, health history, weight loss goals, and individual response profile, our medical team selects the GLP-1 medication and dosing protocol best suited to your needs. Whether semaglutide or tirzepatide is right for you depends on factors unique to your metabolic picture.
Physician-guided dosing optimization: Our providers carefully manage the titration process, adjusting dose timing and escalation based on your tolerance and response. This individualized approach minimizes side effects while maximizing efficacy.
Ongoing monitoring and support: Your dedicated Membership Manager provides continuous support, while regular follow-up labs track your metabolic health markers throughout treatment. This proactive monitoring allows us to adjust your protocol as your body changes, ensuring you stay on track toward your goals.
Ready to explore whether a GLP-1 program is right for you? Book a free virtual call to discuss your goals with our team.
Frequently Asked Questions About GLP-1 Weight Loss
How much weight can I lose on GLP-1 medications?
Clinical trials show average weight loss of 15 to 22 percent of body weight with semaglutide and up to 26 percent with tirzepatide over 68 to 72 weeks. Individual results vary based on starting weight, medication choice, dosage, and adherence to lifestyle recommendations.
How quickly do GLP-1 medications start working?
Most patients notice reduced appetite within the first 1 to 2 weeks. Measurable weight loss typically begins within 4 to 8 weeks. Maximum results generally occur at 12 to 18 months of consistent treatment.
Are GLP-1 medications safe for long-term use?
Current evidence supports the long-term safety of GLP-1 receptor agonists. Semaglutide has safety data extending beyond two years (STEP 5 trial), and liraglutide has over a decade of post-market safety data. Ongoing monitoring by a qualified healthcare provider is recommended.
Do I need to follow a specific diet while taking GLP-1 medications?
While no specific diet is required, a balanced, protein-rich diet enhances results and helps preserve lean muscle mass during weight loss. Your medical team can provide personalized nutritional guidance based on your metabolic profile and goals.
Can I take GLP-1 medications if I don’t have diabetes?
Yes. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults without diabetes who meet BMI criteria. You do not need a diabetes diagnosis to qualify.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist that targets one incretin pathway. Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates two pathways simultaneously. Clinical trials suggest tirzepatide may produce greater weight loss on average, though individual responses vary. A medical provider can help determine which medication is best for your situation.
Will my insurance cover GLP-1 medications for weight loss?
Insurance coverage varies significantly by plan and carrier. Some plans cover FDA-approved weight loss medications (Wegovy, Zepbound, Saxenda), while others do not. Compounded semaglutide may offer a more accessible option for those without coverage.
What happens if I experience side effects?
Most side effects are mild and temporary, improving as your body adjusts. Your prescribing provider can slow the titration schedule, adjust the dose, or recommend supportive strategies. In rare cases, switching to a different GLP-1 medication may be appropriate.
Can I exercise while on GLP-1 medications?
Absolutely. Regular exercise, particularly strength training, is strongly encouraged alongside GLP-1 therapy. Exercise helps preserve lean muscle mass, supports metabolic health, and enhances long-term weight maintenance outcomes.
How is 1st Optimal’s GLP-1 program different from other online weight loss clinics?
1st Optimal provides comprehensive lab testing before prescribing, personalized medication selection based on your metabolic data, physician-guided dosing optimization, and ongoing monitoring through a dedicated Membership Manager. Our approach is grounded in functional medicine principles and data-driven care, not a one-size-fits-all prescription.
Reviewed by Joe Miller, BS Kinesiology & Exercise Science | A4M Fellowship | NASM Certified | NSCA CSCS
